Genmab — Januar 2020
-
DnB Markets Rune Majlund Dahl
Genmab (Hold, TP: DKK1685.00) - Watch out for high costs in 2020e
With the 2019 Darzalex sales figure not yet passed from JNJ to Genmab, we believe it must be close to USD3bn. Hence, we cautiously move the USD150m sales milestone from 2019e to 2020e, assuming global Darzalex sales below USD3bn. We expect significantly higher operating costs than consensus in the 2020 guidance, which we believe could be a negative trigger in the -
I actually think the most interesting part is that they now lean towards missing the milestone, but they keep their price target the same. (which can be a bit reassuring for the many here that think we will fall of the cliff if we miss the 3bn slightly)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind